Issue Information
26 October 2017
Issue Information
26 October 2017
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus–infected patients treated with direct‐acting antivirals
Federico Piñero, Marcelo Silva – 25 October 2017
Periostin promotes malignant potential by induction of epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma
Masaaki Mino, Keishi Kanno, Kousuke Okimoto, Akiko Sugiyama, Nobusuke Kishikawa, Tomoki Kobayashi, Junya Ono, Kenji Izuhara, Tsuyoshi Kobayashi, Toshikazu Ohigashi, Hideki Ohdan, Susumu Tazuma – 25 October 2017 – Periostin, a secreted matricellular protein, has been reported to induce epithelial‐mesenchymal transition (EMT), which increases motility and invasiveness in various epithelial cancer cells.
LiverLearning®: 2017 Hepatitis Debrief
This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.Michael W. Fried Insook Kim Insook Kim, PhD is a clinical pharmacology team leader for gastroenterology and hepatology products in the Office of Clinical Pharmacology at FDA. Since she joined FDA as a clinical pharmacology reviewer in 2007, she has been involved in numerous IND and NDA review and has provided regulatory and scientific guidance for product development in the areas of gastroenterology, hepatology, and inborn errors of metabolism.
LiverLearning®: Leon Schiff SOA: Acute on Chronic Liver Failure
As HCV therapies now achieve high rates of SVR across a broad spectrum of individuals in patient care, there is a need to consider those HCV-infected persons who are not or may have difficulty accessing care or engaging in HCV therapy. Additionally, aspects related to prevention of reinfection are relevant in these difficult to reach populations.
LiverLearning®: 2017 Clinical Hepatology Debrief
This session will provide a summary of the clinical highlights from The Liver Meeting®.Michael W. Fried Kris V. Kowdley
LiverLearning®: 2017 NAFLD Debrief
This newly added session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from the meeting.Michael W. Fried Kymberly Watt
Genetic association studies and the risk factors for developing the “Immuno‐bile‐logic” disease primary biliary cholangitis
Evaggelia Liaskou, Gideon M. Hirschfield – 24 October 2017
LiverLearning®: AASLD/EASL Symposium: Non-invasive Assessment of Liver Disease
The Symposium will provide a broad overview on the diversity of noninvasive diagnostic approaches for assessing chronic liver disease in the U.S. and Europe. Experts will discuss the role and interpretation of noninvasive diagnostic test strategies in assessing the severity of disease associated with NAFLD, cirrhosis, and portal hypertension. These lectures — in conjunction with a panel discussion — will benefit all healthcare professionals using these novel tools in their clinical practice.Jayant A. Talwalker Sumeet K.